A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKim T. Blackwell, M. S. Berger, Eli Kaplan et al.|Journal of Clinical Oncology|2004Cited by 44
Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA studyVéronique Dièras, Lorenzo Gianni, Manfred Welslau et al.|Cancer Research|2016Cited by 0